Clinical Trial: A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants with Obesity or Overweight with Type 2 Diabetes

U.S., March 29 -- ClinicalTrials.gov registry received information related to the study (NCT06901349) titled 'A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants with Obesity or Overweight with Type 2 Diabetes' on March 24.

Brief Summary: The main purpose of this study is to see how well and how safely bimagrumab, tirzepatide, and the combination, work in lowering body weight in participants with obesity or overweight and type 2 diabetes. Participation in the study will last about 13 months.

Study Start Date: June, 2025

Study Type: INTERVENTIONAL

Condition: Obesity Overweight

Intervention: DRUG: Bimagrumab

Administered SC

DRUG: Tirzepatide

Administered SC

DRUG: Bimagrumab Placeb...